HOUSTON--(BUSINESS WIRE)--SpinalCyte, LLC, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the Australian Patent Office issued a Notice Of Acceptance on its patent application “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor” to regrow the spinal disc, using human dermal fibroblasts. The allowed claims include the use of human dermal fibroblasts from the patient’s own body, to regrow the nucleus of the spinal disc in vivo. The cell-based therapy uses the dermal cells to differentiate into cartilage type cells necessary to regrow the nucleus pulposus.
